tbuckley/cabot-search huggingface dataset:
A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).
Authors: J. C. Chisholm, M. Casanova, B. Geoerger, J. H. Merks, G. Massimini, N. Moore, I. A. Rooney, L. Viviers, O. Oberlin
Journal: Journal of Clinical Oncology (2010)

TPS330 Background: Goals of this study, conduct of which was agreed with the European Medicines Evaluation Agency, are to evaluate the efficacy and safety profile of bevacizumab (Bv) administered with chemotherapy in metastatic RMS and NRSTS in childhood and adolescence, and to characterize the pharmacokinetic (PK) profile of Bv across all age subsets of the study population. Despite therapeutic advances, outcomes of metastatic RMS and NRSTS remain poor. Preclinical reports implicate angiogenesis in the pathogenesis of these tumors (Cancer Res 2006; 66:8770-78). Bevacizumab (Bv), a recombinant humanized monoclonal antibody to VEGF (Cancer Res 1997; 57:4593-99), is approved in several oncology indications in adults. A recent phase I study (J Clin Oncol 2008; 26:399-405) indicated that Bv is well tolerated in children with refractory solid tumors and yielded PK data that support further studies of Bv in childhood cancer. Methods: Approximately 150 patients, aged from > 6 months to < 18 years, who present with metastatic RMS or NRSTS, will be randomized to receive 18 months of standard combined modality therapy, as currently recommended by the European Soft Tissue Sarcoma Group, either alone or with Bv. Treatment will be in two phases: induction therapy [9 three-weekly cycles including 4 cycles of IVADo (ifosfamide, vincristine, actinomycin D and doxorubicin) followed by 5 cycles of IVA (i.e., without doxorubicin)] and maintenance therapy (twelve 4-weekly cycles of vinorelbine and cyclophosphamide). Local therapy will be considered after the 6th induction cycle. Primary endpoint will be event-free survival. PK sampling will be performed on all patients randomized to the experimental arm during the first 4 cycles of induction. After the primary efficacy and safety analysis, all patients who have not met the primary endpoint will be followed for at least 47 months for survival and long-term effects of treatment. The study enrolled 17 patients between July 2008 and December 2009. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche
Dr Hoover responds to Dr Moertel.
Authors: H C Hoover
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.3.586 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8445435 Dr Hoover responds to Dr Moertel. H C Hoover JrxH C Hoover JrSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.3.586 PDF "Dr Hoover responds to Dr Moertel.." Journal of Clinical Oncology, 11(3), p. 586© 1993 by American Society of Clinical Oncology
Utilization review of treatment of suicide attempters: chart review as patient care evaluation
Authors: L Kirstein, M M Weissman
Journal: American Journal of Psychiatry (1975)

The authors reviewed the charts of 36 nonhospitalized suicide attempters who were identified by utilization review as requiring hospitalization. In 16 of the cases, the authors judged the treatment given to have been adequate because of an absence of a history of psychiatric treatment and/or the rapidity with which outpatient treatment was instiituted. Ten of the cases were judged to have been inadequately treated. This finding pointed to have been inadequately treated. This finding pointed to specific deficiencies in the training of residents and the delivery of psychiatric services and illustrates how chart review can be used to upgrade psychiatric care.
Study on compound herbal medicine LC07 treating chemotherapy-induced peripheral neuropathy
Authors: S. Lei, L. Jia, Y. Lou
Journal: Journal of Clinical Oncology (2008)

20735 Background: To explore the effects of Chinese herbal medicine LC07 infusion external treatment on chemotherapy-induced peripheral neuropathy. Methods: We tested LC07 infusion external treatment for 4 weeks in 32 patients with peripheral neuropathy grade ≥1 (National Cancer Institute- NCI) or hand-foot-syndrome (HFS) grade ≥1 (Common Toxicity Criteria- CTC) during or after paclitaxel or oxaliplatin or capecitabine therapy. 0.5% LC07 infusion soaked the feet and hands, 30min,Bid. An independent researcher assessed patients before and after LC07. Curative: Grade 0 or symptoms disappear completely. Effective: Grade decreases more than 1 level. Total efficiency: effective and curative. Results: All patients except two reported symptom relief without any side effect as tetter, allergy or other uncomfortable. Total effective of all patients was 93.8% (30/32), curative 56.2% (18/32).Visual Analogue Scale (VAS) on spontaneous pain decreased from 5.5 to 1.6 (P<0.01). The average time from therapy beginning to effective is 5.7±3.2 days. 11 patients who had experienced oxaliplatin-caused peripheral neuropathy status last chemotherapy cycle 21.2±13.1 days, compared with neuropathy status this chemotherapy cycle with LC07 therapy 7.9±3.6 days (P<0.01). Conclusions: LC07 (compound herbal medicine including Herba Geranii and Aconiyum carmichaeli) is effective and convenient in clinical without any side effect which can treat chemotherapy-induced peripheral neuropathy. Thus improve quality of life and help chemotherapy progress. No significant financial relationships to disclose.
Psychotoxicity from antineoplastic agents.
Authors: F Fernandez
Journal: Journal of Clinical Oncology (1987)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1987.5.2.319 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3806176 Psychotoxicity from antineoplastic agents. F FernandezxF FernandezSearch for articles by this author https://doi.org/10.1200/JCO.1987.5.2.319 PDF "Psychotoxicity from antineoplastic agents.." Journal of Clinical Oncology, 5(2), pp. 319–320© 1987 by American Society of Clinical Oncology
Gender difference in susceptibility to smoking in Korean lung cancer patients having smoking habits
Authors: J. Ryu, H. Lee, J. Cho, S. Kwak, H. Lee, M. Lee, M. Lee, C. Kim
Journal: Journal of Clinical Oncology (2006)

17158 Background: There were some controversies whether women were more or less susceptible to the carcinogenic effect of cigarette smoke and the decline of forced expiratory volume in 1 second (FEV 1 ) to pack-years compared to men. Methods: In this study, we included all lung cancer patients having smoking habits who was histologically diagnosed and performed pulmonary function testing at the time of diagnosis from September 2001 through December 2005. We estimated individual susceptibility to smoking using a formula (SI, susceptibility index) of (100% predicted FEV 1 )/pack-years. Results: Of 858 lung cancer patients, sex ratio (M/F) was 14.6 (803/55). Past smokers were in 236 (29.3%) for men, 11 (20.0%) for women. Most common hsitologic type was squamous cell carcinoma (477), adenocarcinoma (191), small cell carcinoma (147), adenosquamous cell carcinoma (14), large cell carcinoma (14), NSCLC cell type not specified (15). Pack-years were 41.3 ± 18.9 for men, 29.2 ± 20.4 for women (P = 0.000). FEV 1 % was 78.7 ± 23.3 for men, 79.4 ± 22.9 for women (P = 0.832). As for SI, there were no differences between men (0.65 ± 1.1) and women (0.72 ± 1.6) (P = 0.688). Conclusions: Although lung cancer women having smoking habits showed lower pack-years, there were no gender differences in terms of FEV 1 decline to cigarette smoking. No significant financial relationships to disclose.
Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study
Authors: Laura E. Labonté, Wan C. Tan, Pei Z. Li, Palmina Mancino, Shawn D. Aaron, Andrea Benedetti, Kenneth R. Chapman, Robert Cowie, J. Mark FitzGerald, Paul Hernandez, François Maltais, Darcy D. Marciniuk, Dennis O'Donnell, Don Sin, Jean Bourbeau
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Chronic obstructive pulmonary disease (COPD) remains undiagnosed in many individuals with persistent airflow limitation. These individuals may be susceptible to exacerbation-like respiratory events that consume health care resources.To compare exacerbation-like respiratory events, event prevalence, and differences in the odds of using medication and/or health services between subjects with diagnosed and undiagnosed COPD.Subjects sampled from the general population participating in the CanCOLD (Canadian Cohort Obstructive Lung Disease) study, with at least 12 months of exacerbation-event follow-up who were classified as having physician-diagnosed or undiagnosed COPD were assessed. Exacerbation-like respiratory events were captured using a questionnaire administered every 3 months.A total of 355 subjects were undiagnosed and 150 were diagnosed with COPD. Undiagnosed subjects were less symptomatic and functionally impaired, had been prescribed fewer respiratory medications, and had better health status. The incidence of reported exacerbation-like events was higher in diagnosed subjects and increased in both groups with the severity of airflow obstruction. Although subjects with diagnosed COPD were more often prescribed medication for exacerbation events, health service use for exacerbation events was similar in both groups.Most subjects with COPD in Canada remain undiagnosed. These subjects are less symptomatic and impaired, which may partly explain lack of diagnosis. Although patients with undiagnosed COPD experience fewer exacerbations than those with diagnosed COPD, they use a similar amount of health services for exacerbation events; thus, the overall health system burden of exacerbations in those with undiagnosed COPD is considerable.
Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration
Authors: Cristian A. Amador, Jean-Philippe Bertocchio, Gwennan Andre-Gregoire, Sandrine Placier, Jean-Paul Duong Van Huyen, Soumaya El Moghrabi, Stefan Berger, David G. Warnock, Christos Chatziantoniou, Iris Z. Jaffe, Philippe Rieu, Frederic Jaisser
Journal: Kidney International (2015)
NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women
Authors: B. Moy, D. Tu, L. E. Shepherd, J. L. Pater, T. J. Whelan, J. N. Ingle, P. E. Goss
Journal: Journal of Clinical Oncology (2006)

6018 Background: Disease free survival was significantly improved in women receiving letrozole after standard adjuvant tamoxifen in the MA.17 trial. Based on the results of MA.17 and of other trials of aromatase inhibitors in early stage breast cancer, chronic aromatase inhibitor therapy, in postmenopausal women free of breast cancer recurrence, is now being widely employed. We analyzed the toxicity of letrozole according to ethnic status among women enrolled in MA.17. Methods: The chi-square test was used for comparison of rates of side effects between the two groups, Caucasian vs. ethnic minority (defined as all non-Caucasians). In a subset of women, quality of life (QOL) was assessed by the SF-36 Health Survey. Mean change scores in QOL from baseline were compared between groups for summary measures and domains using the Wilcoxon test. Results: 352 minority women and 4,708 Caucasians were enrolled in MA.17, of which 183 minority women and 2,339 Caucasians were randomized to receive letrozole. Caucasians were older than minority women and had a slightly longer duration of treatment with prior tamoxifen. Tumor size and nodal status were not significantly different between the two groups. In women who received letrozole, minority women had significantly lower incidence of hot flashes (49% vs. 58%; p = 0.02), fatigue (29% vs. 39%; p = 0.005), and arthritis (2% vs. 7%; p = 0.006) compared with Caucasians. Mean QOL change scores of SF-36 domains for women who received letrozole were not different but minority women had better mental health at 6 month assessment (p = 0.02) and worse bodily pain at 12 month assessment (p = 0.046). Conclusions: Minority women tolerated letrozole considerably better than Caucasians in the MA.17 trial. These preliminary findings suggest that minority women respond differently to letrozole in terms of toxicity. Recent demonstration of genotypic variations in the aromatase gene in different ethnic groups plus likely pharmacogenomic differences suggests that further research is needed to clarify the clinical outcomes of aromatase inhibition in women of diverse ethnicities. Future research strategies should focus on examining in vivo genotype-phenotype correlations to determine the effects of genetic variation on response to anticancer therapy and on toxicities and end-organ effects. [Table: see text]
Abstract 1700: Balloon Expandable Aortic Valve [BEAV] Implantation. The first 100 Canadian patients.
Authors: Sanjeevan Pasupati, Karin Humphries, Abdullah AlAli, Lukas Altwegg, Samuel Lichtenstein, Jian Ye, Anson Cheung, Christopher R Thompson, Ronald Carere, Robert Moss, Brad Munt, May Lee, John Webb
Journal: Circulation (2007)

Objectives: We describe the outcomes in our first 100 transcatheter BEAV patients. This high risk group includes the first-in-man transarterial and transapical patients Methods: Femoral arterial an...
Periodic Nanoneedle and Buffer Zones Constructed on a Titanium Surface Promote Osteogenic Differentiation and Bone Calcification In Vivo
Authors: Peng Yu, Xiaojing Zhu, Xiaolan Wang, Shuangying Wang, Weiping Li, Guoxin Tan, Yu Zhang, Chengyun Ning
Journal: Advanced Healthcare Materials (2015)

Rapid and effective bone mineralization at the bone/implant interface is required for successful orthopedic and dental implants. In this study, two periodic microscale functionalized zones on titanium (MZT) are created, namely, nanoneedle zones and buffer zones. The aim of this design is to provide spatially regulated topographical cues on titanium to enhance the efficacy of bone regeneration. This goal is achieved using a versatile and effective technique in which nanoneedle structures are hydrothermally constructed on the surface of titanium sheets, after which selective laser irradiation is used to construct buffer zones. The zonal structures of the MZT overcome the suppressive effect of the nanoneedle film on osteoblasts. Additionally, the MZT exhibits zone‐selective apatite deposition and protein adsorption. The accelerated in vitro osteoblast differentiation and nodule deposition on the MZT are confirmed. Elemental analysis of the bone nodules formed by the osteoblasts growing on the titanium and MZT demonstrates they have different compositions. Histological and scanning electron microscope analysis of the bone formation on in vivo implants shows that this process is also enhanced by the MZT implant. The concept of constructing functionalized zones on titanium implant could facilitate future research on improving the design of orthopedic and dental implant surfaces.
Death and regeneration of the pancreatic islets in relation to the development of fibrosis in patients with chronic pancreatitis
Authors: N.Y. OSHMYANSKA
Journal: GASTROENTEROLOGY (2014)

The present study was conducted on biopsy material obtained from 65 patients with complicated chronic pancreatitis and 6 samples of tissue from intact pancreas. Сellular composition, islets’ death and regeneration were analyzed using histological and immunohistochemical methods depending on the fibrous transformation in the development of chronic pancreatitis. Given study provides a detailed description of the histological changes that occur in the pancreas during the development of fibrosis, along with expression patterns of pro-apoptotic nucleases Endonuclease G and DNase, and the proliferation markers PCNA and Neurogenin-3 at different stages of chronic pancreatitis.
Safety and Efficacy of Minimally Invasive Video-Assisted Ablation of Pilonidal Sinus
Authors: Marco Milone, Loredana Maria Sosa Fernandez, Mario Musella, Francesco Milone
Journal: JAMA Surgery (2016)

Video-assisted ablation of pilonidal sinus (VAAPS) is a new minimally invasive treatment based on the complete removal of the sinus cavity with a minimal surgical wound.To validate the safety and efficacy of VAAPS.From January 1, 2012, through December 31, 2013, we enrolled 145 consecutive patients from an intention-to-treat population at a single academic center in Italy. The last date of follow-up for this analysis was December 31, 2014. Patients with chronic nonrecurrent pilonidal sinus were randomized to minimally invasive (76 patients) or conventional (69 patients) treatment of pilonidal sinus.VAAPS and Bascom cleft lift procedure.The primary end point of the study was time off work. Secondary end points were the rates of operative success and perioperative complications (infection and recurrence), operative time, patient satisfaction, and intraoperative and postoperative pain ratings.Of the 145 patients, 60 (78.9%) were male and 16 (21.1%) were female in the minimally invasive treatment group, and 54 (78.3%) were male and 15 (21.7%) were female in the conventional treatment group. The mean (SD) age of the patients was 25.5 (5.9) years in the minimally invasive treatment group and 25.7 (5.3) in the conventional treatment group. In the minimally invasive treatment group, mean (SD) time off work was significantly less compared with the conventional treatment group (1.6 [1.7] vs 8.2 [3.9] days; P < .001). Mean (SD) operative time was significantly longer in the minimally invasive treatment group (42.9 [9.8] minutes) vs the conventional treatment group (26.5 [8.7] minutes), P < .001. Although the overall complication rate was similar in both groups, there were fewer infections (1 [1.3%] vs 5 [7.2%]; P = .10) recorded in the minimally invasive treatment group. Similarly, patients enrolled in the minimally invasive treatment group expressed significantly less pain and higher satisfaction.In the new era of minimally invasive treatment surgery, pilonidal sinus could become a disease treated with an endoscopic approach. Although additional studies are needed to provide a definitive conclusion, our results encourage considering the adoption of this treatment as the most effective way to treat pilonidal sinus.clinicaltrials.gov Identifier: NCT01963273.
High HLA-DP Expression and Graft-versus-Host Disease
Authors: Effie W. Petersdorf, Mari Malkki, Colm O’hUigin, Mary Carrington, Ted Gooley, Michael D. Haagenson, Mary M. Horowitz, Stephen R. Spellman, Tao Wang, Philip Stevenson
Journal: New England Journal of Medicine (2015)

Transplantation of hematopoietic cells from unrelated donors can cure blood disorders but carries a significant risk of acute graft-versus-host disease (GVHD). The risk is higher when the recipient and donor are HLA-DPB1-mismatched, but the mechanisms leading to GVHD are unknown. The HLA-DPB1 regulatory region variant rs9277534 is associated with HLA-DPB1 expression. We tested the hypothesis that the GVHD risk correlates with the rs9277534 allele linked to the mismatched HLA-DPB1 in the recipient.
T-Lymphocyte and B-Lymphocyte Subpopulations Infiltrating Human Mammary Carcinomas&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Oleg Eremin
 4, Robin R. A. Coombs, Terence D. Prospero, David Plumb
Journal: JNCI Journal of the National Cancer Institute (1982)

Both T- and B-lymphocytes were found in human primary mammary carcinomas and were distributed in widely varying amounts, but in most tumors, T-lymphocytes predominated. A small percentage of the T-lymphocytes expressed receptors for the Fc portion of IgG (FcγR), but very few had receptors for C3 (C3+) (comparable to the findings in blood). A prominent subset of lymphocytes had FcγR and were C3+, and most of these were surface immunoglobulin (slg)-bearing cells. The majority of lymphocytes from this subset were Fc+ C3+, and only a small percentage were Fc+ C3− (in contrast to the findings in blood). IgD and IgM were the predominant classes of immunoglobulin found on the B-lymphocytes. The different preparative techniques did not result in a selective loss of lymphocyte subsets, but collagenase digestion did lead to a loss of expression of the C3 receptor on the lymphocyte surface, which was recoverable when lymphocytes were reincubated at 37°C. No evidence was found for blocking of the C3 receptor by immune complexes with activated complement.
Abstract 16436: A Dual Role of Cell Adhesion Molecule Necl-4 in Endothelial Cells: Promotion of Migration Under Sparse Conditions and Inhibition of Proliferation Under Confluent Conditions
Authors: Shota Yamana, Amina Tokiyama, Yuya Terao, Ken-ichi Hirata, Yoshiyuki Rikitake
Journal: Circulation (2014)

Background: Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis, and VEGF receptor 2 (VEGFR2) mainly mediates pro-angiogenic activities of vascular endothelial cells (ECs). Recently we have reported that nectin-like molecule (Necl)-5, a member of the immunoglobulin-like cell adhesion molecules Necls, interacts with VEGFR2 and enhances VEGFR2-mediated signaling, leading to increasing pro-angiogenic activities. Here we show that Necl-4, also known as cell adhesion molecule 4 (CADM4), also regulates VEGFR2-mediated pro-angiogenic activities and signaling by a mechanism different form Necl-5, and contact inhibition of proliferation of ECs. Results: Under sparse conditions, Necl-4 was localized at the leading edge of migrating human umbilical vein ECs in culture, and knockdown of Necl-4 increased Rho-associated protein kinase (ROCK) activity and reduced VEGF-induced migration, capillary-like network formation, and activation of Rac1 small GTPase. These reductions were partly restored b...
A predictive method for HCV-related hepatocellular carcinoma by using clinical genomics: meta-analysis of individual patient data
Authors: H. Moriguchi, C. Sato
Journal: Journal of Clinical Oncology (2004)

4069 Background: The incidence of hepatocellular carcinoma (HCC) is increasing because of the dissemination of hepatitis C virus (HCV) infection worldwide. Therefore, an appropriate method to predict HCV-related HCC is needed. Methods: To investigate an association between the mutation in the PKR-binding domain (PKR-bd: NS5A 2209–2274) of the HCV-NS5A protein and the incidence of HCC, sequential data of HCV-1b genomic regions were obtained from available published data (n=82) by the MEDLINE data base and our clinical data (n=125), in which the regions were amplified and directly sequenced from serum samples obtained from 207 patients with chronic liver diseases [HCV-1b infection or HCV-1b-related cirrhosis], 80 with and 127 without HCC. None of them had received interferon therapies. The PKR-bd mutant was defined to have more than 4 amino acid substitutions, the PKR-bd intermediate had 1 to 3 amino acid substitutions, and the PKR-bd wild had no amino acid substitutions. We compared categorical data by the chi-square test. P < 0.05 was considered significant. Results: The incidence of HCV-1b-related HCC in the PKR-bd wild, the PKR-bd intermediate and the PKR-bd mutant was 6/26 (23.1 %), 39/119 (32.8 %) and 35/62 (56.5 %), respectively. Therefore, the incidence of HCV-1b-related HCC was significantly higher in the PKR-bd mutant than the others (mutant vs wild, p=0.004: mutant vs intermediate, p=0.002). Especially, the relative risk for HCV-1b-related HCC in the PKR-bd mutant was 2.45 (95 % CI: 1.17–5.10) compared to the PKR-bd wild. Conclusions: The risk of HCV-1b-related HCC can be predicted by the mutation in the PKR-bd. And, the PKR-bd mutant is super high risk group of HCV-1b-related HCC. No significant financial relationships to disclose.